The following is provided by Navellier with technical comment from South Ocean Management – pls do your own due diligence.
(For this 2021 year, SOM will track only the Top 5 Hi-Growth Investments.)

https://navelliergrowth.investorplace.com/

Navellier says,

High-Growth Investments

The Boston Beer Company, Inc.

The Boston Beer Company, Inc. (SAM) remains well-positioned to benefit from the hard seltzer craze, as well as continuing demand for craft brews. Many folks who are looking to cut calories and carbs have turned to hard seltzers, as evidenced by the more than $4.0 billion in sales in 2020. Recent data from NielsenIQ showed hard seltzer sales soared 160.4% year-over-year in 2020 to $4.14 billion.

Based on the Boston Beer Company’s fourth-quarter results, it grabbed its fair share of the hard seltzer market last year. Company management noted, “The growth of the Truly brand, led by Truly Lemonade Hard Seltzer, continues to be very strong and well ahead of the hard seltzer category.” The Truly brand experienced triple-digit volume growth last year. And to further take advantage of this strength, the Boston Beer Company introduced Truly Iced Tea Hard Seltzer earlier this year.

For the fourth quarter overall, the Boston Beer Company saw a 54% increase in shipments and achieved revenue of $460.9 million, or 53% year-over-year growth. Fourth-quarter earnings surged 135.7% year-over-year to $32.8 million, or $2.64 per share, which topped estimates for earnings of $2.62 per share.

Looking ahead to fiscal year 2021, SAM is focusing its attention on the Truly and Twisted Tea brands in order to maintain its leading position and increase market share as more beverage companies introduce seltzers this year. Full-year 2021 earnings are expect to grow between 28.8% and 54.5%. SAM is a Moderately Aggressive buy below $1,334.

SOM Technicals:

3-27-21: Closed at 1159.99. Trade pressures are neutral. Volumes are  bullish. Testing resistance. The next target up is 1236.

04-03-21: Closed at 1184.68. Trade pressures are up but declining. Volumes are bearish. the next target down is 1145.

04-10-21: Closed at 1253.10. Trade pressures are up. Volumes are bullish. The next target up is 1273.15.

04-16-21: Closed at 1294.93. Trade pressures are up. Volumes are bullish. The next target up is 1368.45.

04-24-21: Closed at 1283.90. Trade pressures are rising into the neutral zone. Volumes are now neutral. The next target up is 1368.

 

Futu Holdings Ltd.

Futu Holdings Ltd. (FUTU), our Chinese online brokerage platform, continues to attract more paying clients throughout Asia and the world. The company added 98,632 paying customers in the fourth quarter, with more than half of these clients from Hong Kong and overseas. At the end of 2020, FUTU had a total of 516,721 paying clients, which represented a 160.5% year-over-year increase.

FUTU also noted that its total number of registered clients jumped 97.8% year-over-year to 1.42 million, while its total number of users rose 58.6% year-over-year to 11.9 million. Thanks to the increase in folks dipping their toes into the financial markets, FUTU also achieved blowout quarterly and yearly results.

For its fourth quarter, FUTU reported total revenue of HK$1.2 billion, or a 281.6% year-over-year increase. Adjusted earnings surged to HK$552.9 million. In U.S. dollar terms, Futu Holdings achieved fourth-quarter revenue of $153 million and adjusted earnings of $71.3 million. Fourth-quarter earnings per ADS surged 880% year-over-year to $0.49, up from $0.05 per ADS in the same quarter a year ago. That topped estimates for earnings of $0.45 per ADS by 8.9%.

For fiscal year 2020, Futu Holdings announced total revenue of $427 million and adjusted earnings of $175.9 million. That represented 213.3% annual revenue growth and 655% annual earnings growth. Full-year earnings per ADS increased 712.5% year-over-year to $1.30, also beating estimates for earnings of $1.19 per ADS.

In the wake of the strong quarterly report, the analyst community increased its full-year outlook in the past week. FUTU’s full-year 2021 earnings are now forecast to soar 148.7% year-over-year to $2.96 per ADS, up from previous estimates for $2.40 per ADS. FUTU is an Aggressive buy below $156.

SOM Technicals:

03-27-21: Closed at 114.69. Trade pressures are down but rising. Volumes are bullish. The next target up is 131.56.

04-03-21: Closed at 153.60. Trade pressures are up. Volumes are bullish. The next target up is 186.42.

04-10-21: Closed at 156.70. Trade pressures are up. Volumes are neutral. The next target up is 186.42.

04-16-21: Closed at 153.01. Trade pressures are up into the neutral zone. Volumes are now neutral. Consolidating at the 153 target. 

04-24-21: Closed at 143.81. Trade pressures are up. Volumes are now neutral. The net target up is the 188.39 level. 

 

Horizon Therapeutics Ltd.

Horizon Therapeutics Ltd. (HZNP) develops treatments for rare and rheumatic diseases. The company’s current portfolio includes 10 medicines that are available in the U.S.: KRYSTEXXA for gout; DUEXIS, PENNSAID, RAYOS and VIMOVO for inflammation; TEPEZZA for ophthalmology; and ACTIMMUNE, BUPHENYL, PROCYBSI and RAVICTI for rare diseases. Horizon Therapeutics also recently acquired Viela, which expands the company’s pipeline to include UPLIZNA, a treatment for a rare autoimmune disease.

Thanks to its expanding pipeline and strong sales of KRYSTEXXA and TEPEZZA, Horizon Therapeutics achieved record results in the fourth quarter of 2020. In the fourth quarter, KRYSTEXXA sales accounted for $128.9 million, while TEPEZZA sales came in at $343.7 million. Total fourth-quarter sales soared 105% year-over-year to $745.3 million.

Horizon Therapeutics also reported that fourth-quarter earnings surged 129% year-over-year to $1.28 per share, up from $0.56 per share in the same quarter a year ago. The consensus estimate called for earnings of $1.06 per share on $693.54 million, so HZNP topped earnings estimates by 20.8% and sales forecasts by 7.5%.

Looking forward to fiscal year 2021, Horizon Therapeutics continues to expect double-digit revenue growth. Full-year revenue is expected to be between $2.7 billion and $2.8 billion, up from $2.2 billion in fiscal year 2020. HZNP is a Moderately Aggressive buy below $94.

SOM Technicals:

03-27-21:Closed at 83.01. Trade pressures are down. Volumes are bearish. The next target down is 76.28.

04-03-21: Closed at 90.50. Trade pressures are up. Volumes are bullish. The next target up is the prior high at 98.54.

04-10-21: Closes at 91.48. Trade pressures are up into the neutral zone. Volumes are bullish. The next target up is 93.80, the upside resistance.

04-16-21: Closed at 93.24. Trade pressures are up but declining. Volumes are bullish. A close below 92.56 would signal lower.

04-24-21: Closed at 94.63. Trade pressures are up. Volumes are bullish. The next target up is 98.43.

 

Logitech International

Logitech International (LOGI) has done it again. The company boosted its outlook for fiscal year 2021 for the fourth time in the past three months! Clearly, Logitech is continuing to experience strong demand for its computer and at-home office products—headsets, keyboards, mice, speakers, webcams, etc.—amidst the global pandemic.

Logitech’s fiscal year 2021 draws to a close at the end of March, and it looks like the company will unveil record results. For fiscal year 2021, Logitech expects sales to increase 63% year-over-year, compared to previous forecasts for 57% to 60% annual sales growth. Operating income is also forecast to be about $1.1 billion, up from previous estimates for $600 million.

In response to the new guidance, the analyst community has also increased estimates for Logitech’s fourth quarter in fiscal year 2021. For the fourth quarter, earnings are expected to double to $0.84 per share and sales are forecast to jump 54.1% year-over-year to $1.09 billion. LOGI is a Conservative buy below $111.

SOM Technicals:

12-19-20: Closed at 94.85. Trade pressures are up. Volumes are bullish. In the move up from 86.80. The next target up is 99.86.

12-26-20: Closed at 92.96. Trade pressures are down into the neutral zone. Volumes are neutral. The next target up is the prior high at 95.94.

01-01-21: Closed at 97.19. Trade pressures are up. Volumes are bullish. The next target up is 99.86.

01-08-21: Closed at 104.85. Trade pressures are up. Volumes are bullish. Zipped thru the 99.86 level; at the 105.70 target. Expect some retracement.

01-16-21: Closed at 100.91. Trade pressures are down. Volumes are bearish. Now in the new short. The next target down is 97.12 which is also a support level.

01-22-21: Closed at 104.20. Trade pressures are up. Volumes are bullish. Testing the 105 highs.

02-26-21: Closed at 108.50. Trade pressures are down but rising. Volumes are neutral. The next target down is 102.28.

03-05-21: Closed at 95.19. Trade pressures are down. Volumes are bullish. Found support at the 91.99 downside target.

03-13-21: Closed at 98.96. Trade pressures are up. Volumes are bearish. The next target up is 102.26.

03-20-21: Closed at 101.67. Trade pressures are up. Volumes are bullish. The next target up is 105.86.

03-27-21: Closed at 103.99. Trade pressures are down but rising. Volumes are bullish. The next target up is 113.20.

04-03-21: Closed at 107.98. Trade pressures are up. Volumes are bullish. The next target up is 113.20.

04-10-21: Closed at 109.01. Trade pressures are in the neutral zone. Volumes are bullish. The next target up is 113.20. 

04-16-21: Closed at 113.45. Trade pressures are up. Volumes are bullish. The next target up is 114.96.

04-24-21: Closed at 117.60. Trade pressures are up. Volumes are bullish. The next target up is 124.60.

 

Novavax, Inc.

Novavax, Inc. (NVAX) is making its seventh-straight appearance on the Top 5 Stocks list this month, as it continues to aid in the fight against the coronavirus. You may recall that Novavax develops vaccines for the toughest viruses in the world, including the coronavirus. Recently, the company revealed that its vaccine, NVX-CoV2373, had a final efficacy of 96.4% against COVID-19, based on its Phase 3 trial in the U.K. Its South African Phase 2b trial demonstrated 55.4% efficacy against HIV-negative trial patients.

Overall, Novavax announced that NVX-CoV2373 offered 100% protection against hospitalization and death from COVID-19. Company management commented, “We are very encouraged by the data showing NVX-CoV2373 not only provided complete protection against the most severe forms of disease, but also dramatically reduced mild and moderate disease across both trials.”

Novavax plans to submit this data to global regulatory agencies and seek authorization for its COVID-19 vaccine. I should add that Novavax’s vaccine can be stored at normal refrigerator temperatures, and it has secured agreements to deliver about 300 million doses of the vaccine. Novavax is also in talks with the FDA and plans to file an emergency use authorization in the second quarter. NVAX is an Aggressive buy below $282.

SOM Technicals:

9-26-20: Closed at 113.56. Trade pressures are up. Volumes are bullish. The next target up is 129.69.

10-11-20: Closed at 111.12. Trade pressures are up and trending. Volumes are bullish. The next target up is 129.00.

10-17-20: Closed at 107.04. Trade pressures are down. volumes are bearish. A close below 101 would signal lower.

10-24-20: Closed at 93.13. Trade pressures are down and trending. Volumes are bullish. the next target down is 73.45.

10-30-20: Closed at 80.71. Trade pressures are down but rising. The next target down is 73.45. A close above 117.39 would start a new move up.

11-07-20: Closed at 89.86. Trade pressures are up but reversing. Volumes are bullish. Need a close above the 25×5 at 98 to restart the move up.

11-14-20: Closed at 96.60. Trade pressures are up. Volumes are bullish. A close above 100 would signal higher.

11-20-20: Closed at 86.60. Trade pressures are down. Volumes are bearish. At resistance. The next target down is 73.45. A break of the resistance would signal higher to 117.39.

11-29-20: Closed at 126.20. Trade pressures are up. Volumes are neutral. Thru the 117 target and now at the 123 target. The next target up is 160.90.

12-05-20: Closed at 126.25. Trade pressures are up but declining. Volumes are neutral. In a retracement inside the move up. The next target down is 94.06.

12-11-20: Closed at 124.88. Trade pressures are up. Volumes are bearish. The next target up is 162.34.

12-19-20: Closed at 124.85. Trade pressures are up into the neutral zone. Volumes are neutral. Need a break above the 136.00 level to establish a new long.

12-29-20: Closed at 129.34. Trade pressures are up. Volumes are neutral. A close above 133.09 would signal a new move up.

01-01-21: Closed at 111.54. Trade pressures are down. Volumes are bearish. Closed below the 25×5 MA . The next target down is 94.09.

01-08-21: Closed at 121.69. Trade pressures are up but reversing. Volumes are bearish. The next target down is 94.09.

01 -16-21: Closed at 127.43. Trade pressures are up. Volumes are bullish. Have closed above the upper median line. the next target up is the prior high at 150.50.

01-22-21: Closed at 126.98. Trade pressures are down but rising. Volumes are bearish. Support is 105.70.

01-29-21: Closed at 220.69. Trade pressures are up. Volumes up huge on the vaccine trial news, but finished as neutral. The next target up is 248.09.

02-05-21: Closed at 290.18. Trade pressures are up. Volumes are now neutral. Past all near term targets. A double in 20% percent of the portfolio makes the returns soar.

02-12-21: Closed at 289.76. Trade pressures are down into the neutral zone. Volumes are neutral. The next target down is 275.27.

02-19-21: Closed at 277.88. Trade pressures are rising into the neutral zone. Volumes are now neutral. Bounced off support at 250.00.

02-26-21: Closed at 238.42. Trade pressures are down. Volumes are bearish. The next target down is 149.15.

03-05-21: Closed at 174.84. Trade pressures are down. Volumes are bullish. Found support at the 149.15 downside target.

03-13-21: Closed at 202.77. Trade pressures are up. Volumes are bullish. The next target up is 260.18.

03-20-21: Closed at 228.25. Trade pressures are up but declining. Volumes are bullish. The next target up is 260.18.

03-27-21: Closed at 181.84. Trade pressures are down but rising. Volumes are  bearish. The next target down is 147.39.

04-03-21: Closed at 187.17. Trade pressure are up. Volumes are neutral. In the second leg up, but indecisive. Need a close above the 25×5 at 213.48 to get going again.

04-10-21: Closed at 179.51. Trade pressures are up. Volumes are still neutral.  The next target up is the new long entry at 200.62.

04-16-21: Closed at 227.35. Trade pressures are up. Volumes are bullish. The new long entry brought in buyers and a big move up. The next target up is 260.18.

04-24-21: Closed at 207.92. Trade pressures are down. Volumes are bullish. The next target down is the 171.90 support.